STORM’s METTL3 Inhibitor Effective Against AML

Plans Global Clinical RNA Epigenetic Drug Program in early 2022

Apr 28 2021

• By Sten Stovall

STORM is targeting RNA modifying enzymes for development of new anti-cancer drugs • Source: Informa

More from Emerging Company Profiles

More from Start-Ups & SMEs